MD Anderson Cancer Center

Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Two Patient Cohorts

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Pharmaceutical, Managed Care, Oncology, General Health, Health, FDA, Clinical Trials, NMIBC, BCG, Toxicity, HG, Physician, Congress, Nadofaragene firadenovec, Survival, PD, Cystectomy, Ferring Pharmaceuticals, Patient, Aes, EAU, MD Anderson Cancer Center, University, Month, Carcinoma in situ, Safety, Division, Probability, CIS, Food, Pharmaceutical industry

“Intravesical gene therapy represents an important innovative treatment option for these patients.

Key Points: 
  • “Intravesical gene therapy represents an important innovative treatment option for these patients.
  • The efficacy analysis included 103 and 48 patients in the CIS and PD cohorts, respectively, who met the protocol definition of BCG-unresponsive NMIBC.
  • In total, 12.1% (13/107) and 20.0% (10/50) of patients in the CIS and PD cohorts, respectively, received ADSTILADRIN at three years.
  • In the CIS cohort, about 53% achieved a complete response (CR) at Month 3 in the primary analysis.

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, Colorectal cancer, Cetuximab, Progression-free survival, Patient, FACP, Bristol Myers Squibb, University, MD Anderson Cancer Center, AACR, Pacific Time Zone, CRC, FDA, PDUFA, Pharmaceutical industry

The data will also be published simultaneously in Cancer Discovery .

Key Points: 
  • The data will also be published simultaneously in Cancer Discovery .
  • The safety profile for KRAZATI plus cetuximab was manageable and consistent with previous reports, and with the known safety profile of each drug individually.
  • In previous studies, treatment with cetuximab as a single agent did not offer a clinical benefit in patients with KRAS-mutated colorectal cancer.
  • KRAZATI is a registered trademark of Mirati Therapeutics, Inc., a Bristol Myers Squibb company.

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 22, 2024
Research, Topotecan, TC, LSD1, Survival, Bone marrow, Progression-free survival, DCR, Patient, Acquisition, Deuterium, NHL, IND, Myelodysplastic syndrome, Non-Hodgkin lymphoma, Clinical trial, Azacitidine, Chronic myelomonocytic leukemia, Probability, Cyclophosphamide, FDA, MD Anderson Cancer Center, Ewing sarcoma, Consultant, Food, Pharmaceutical industry

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2023 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $5.9 million as of December 31, 2023, compared with $12.1 million as of December 31, 2022.
  • In August 2023 Salarius announced a comprehensive review of strategic alternatives focused on maximizing shareholder value.
  • Research and development expenses were $0.06 million for the fourth quarter of 2023, compared with $4.7 million for the fourth quarter of 2022, reflecting the above-mentioned cost-savings plan.
  • Net cash used for operating activities during the fourth quarter of 2023 was $1.5 million, compared with $4.7 million during the same quarter in 2022, reflecting the above-mentioned cost-savings plan.

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Retrieved on: 
Friday, March 22, 2024
MYGN, Diagnosis, Genetic testing, Patent, Combinatorics, Genetics, Patient, Neoplasm, Research, DNA, Myriad Genetics, Doctor of Philosophy, Oncology, Medicine, University, MD Anderson Cancer Center, MRD, Intellectual property, FDA, Estate (law), Pharmaceutical industry

U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.

Key Points: 
  • U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
  • This method describes a key aspect of tumor-informed MRD assays that detect circulating tumor DNA (ctDNA) through sequencing.
  • Specifically, the patented method relates to the manner in which a sample is sufficiently enriched with ctDNA that it can be detected, if present, with high sensitivity and specificity.
  • “The 2016 filing date of this patent—at the advent of MRD development—highlights Myriad’s foresight about the potential role of tumor-derived cell-free DNA in the expanding field of cancer diagnostics,” said Paul J. Diaz, President and CEO, Myriad Genetics.

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Retrieved on: 
Thursday, March 21, 2024
Cancer, Principal, Enzyme, DNA repair, Biochemistry, Survival, Professor, Monroe Dunaway Anderson, Patient, Neoplasm, DNA, History, Breast, Prostate, Protein, University, MD Anderson Cancer Center, PARP, Therapy, ALC1, Chromatin, CSO, LP, Pharmaceutical industry

EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.

Key Points: 
  • EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.
  • By hindering DNA repair, PARP inhibitors cause tumor cell death, and they have been effective therapies for many ovarian, breast, prostate, and pancreatic cancers.
  • EIS-12656 inhibits the chromatin remodeling enzyme ALC1, which is critical to the DNA repair process associated with PARP activation.
  • EIS-12656 was developed by Eisbach to disrupt DNA-damage-dependent PARP activation at an early stage of the repair process.

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Retrieved on: 
Thursday, March 21, 2024
Stroke, Netherlands Cancer Institute, Conference, Development, Immunotherapy, GSK, Patient, Lung, DSM-IV codes, National Cancer Institute, MD Anderson Cancer Center, University, Doctor of Philosophy, NIH, Senior, Sarcoma, Clinical trial, Annual report, Bangladesh Technical Education Board, Squamous-cell carcinoma, OCCC, Pharmaceutical industry

PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.

Key Points: 
  • -- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers --
    PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc .
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.
  • The clinical trial was initiated by, and is being conducted at, the University of Texas MD Anderson Cancer Center.
  • Dr. Bernards is a member of the Board of Directors of LIXTE.

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, March 13, 2024
AXL, PIN, Neutropenia, Growth, Rituximab, Sarcoma, ALT, NSCLC, ASH, FY, Progression-free survival, Skin infection, Patient, Follicular lymphoma, S&M, Research, EDT, Aes, Periodic breathing, G&A, University, Lung cancer, Insurance, AACR, DLT, Pancreatic cancer, Hyperglycemia, Society, Therapy, Clinical trial, Diffuse large B-cell lymphoma, PFS, CD22, ADC, Data, Fatigue, MD Anderson Cancer Center, FDA, DLBCL, Marketing, PSMA, IDMC, Pharmaceutical industry

LAUSANNE, Switzerland, March 13, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided business updates.

Key Points: 
  • “In the fourth quarter we saw results of our strategy in action across a number of key areas.
  • A return to sequential quarter-over-quarter growth in the fourth quarter of 2023 followed the restructuring of the commercial model, with sales volume increasing in both community and academic settings.
  • R&D expenses were $30.3 million for the fourth quarter and $127.1 million for full year 2023, compared to $48.1 million and $186.5 million, respectively, for the fourth quarter and full year 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss fourth quarter and full year 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Retrieved on: 
Saturday, April 6, 2024
Research, Women, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Oncology, Orbis, Urinary tract infection, Cardiac arrest, Stomatitis, Patient, Stroke, Lung cancer, University, Acute kidney injury, Neoplasm, Therapy, Anemia, Vomiting, Pleural effusion, Cellulitis, Shock (mechanics), Periodic breathing, Colorectal cancer, Abdominal pain, Safety, Immunohistochemistry, Fatigue, ADC, Daiichi Sankyo, Food, IHC, Sepsis, NSCLC, Appetite, Biliary tract, Constipation, NCCN, MD, Priority review, Fatality, Pneumonitis, HER2, ILD, Medication, Pneumonia, AstraZeneca, COVID-19, Biomarker, Diarrhea, Bleeding, MD Anderson Cancer Center, Nausea, Upper respiratory tract infection, Pharmaceutical industry

The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive (IHC 3+) solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02 , DESTINY-Lung01 or DESTINY-CRC02 .

Key Points: 
  • The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive (IHC 3+) solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02 , DESTINY-Lung01 or DESTINY-CRC02 .
  • In DESTINY-PanTumor02, efficacy was assessed in a subgroup of previously treated patients (n=111) with centrally or locally assessed HER2 positive (IHC 3+) solid tumors including either biliary tract, bladder, cervical, endometrial, ovarian, pancreatic or other tumors.
  • In DESTINY-Lung01, efficacy was assessed in a subgroup of patients (n=17) with centrally confirmed HER2 positive (IHC 3+) non-small cell lung cancer (NSCLC).
  • In DESTINY-CRC02, efficacy was assessed in the subgroup of patients (n=64) with centrally confirmed HER2 positive (IHC 3+) colorectal cancer.

NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Inflammation, Harvard Medical School, DSP, Development, Gene expression, Immunotherapy, IL-6, Triple-negative breast cancer, RNA, King's College London, Immunology, Tumor microenvironment, Cancer, University, NanoString Technologies, Senior, Biology, Abstract, Pancreatic cancer, Neoplasm, Research and development, Hospital, Cell, SMI, MD Anderson Cancer Center, Blind spot, Medical imaging

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.

Key Points: 
  • NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.
  • The conference will be held in San Diego, April 5-10, 2024.
  • NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms.
  • “NanoString customers are using the highest plex protein and RNA spatial biology panels commercially available on cancer patient samples, making fundamental discoveries and answering key questions about patient response to advanced cancer therapies utilized today.

Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes

Retrieved on: 
Thursday, April 4, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Diagnosis, PCR, Plasma, Carcinoma, Cancer cell, Protocol, Biomarker, DNA, Classification, University, MD Anderson Cancer Center, DNA methylation, AACR, Liquid biopsy, SCLC, Medical imaging

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.
  • The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10.
  • The 13-marker PCR assay developed for this pilot study stemmed from data from a recent study published in Cancer Cell demonstrating the detection of SCLC using DNA methylation in plasma samples from heavy smokers, yielding a sensitivity of 94% and specificity of 95%.
  • In the data being presented at AACR, the 13-marker PCR assay correctly classified 97% of the SCLC tissue samples in a blinded cohort.